Sugemalimab (Cejemly® in China), the first PD-L1 inhibitor for mNSCLC developed independently in China, is a high-affinity, fully humanized, full-length anti-PD-L1 IgG4 monoclonal antibody that selectively binds PD-L1 and blocks its interaction with PD-1 and the leukocyte differentiation antigen CD80 to exert anti-tumor effects. Here, CD274 is linked to neoplasm.